cardiovascular

News

HDL Therapeutics eyes public listing in $480m SPAC deal

US medical device company HDL Therapeutics is aiming to list on the Nasdaq via a merger with Swiftmerge Acquisition, a special purpose acquisition company (SPAC).

News

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in

News

Roche buys into Alnylam's twice-yearly blood pressure drug

Roche has paid $310 million upfront for rights to Alnylam Pharma's zilebesiran for hypertension, a handsome sum for a drug that so far has only generated phase 1 data.

News

Astellas taps Eko digital stethoscope for heart failure DTx

Astellas has licensed rights to a smart stethoscope device developed by Eko Health, that it will use as part of a digital therapeutic (DTx) approach to heart failure.

News

AI-based heart disease tool wins Future NHS Award

A digital tool developed by researchers in the NHS that is being used to speed up the diagnosis of heart disease has won this year’s Future NHS Award, which recognises out

News

Novartis will appeal Entresto patent setback

Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to t

HDL Therapeutics eyes public listing in $480m SPAC deal

Dosing prompts Novartis to tap Ionis for second Lp(a) drug

Roche buys into Alnylam's twice-yearly blood pressure drug

Astellas taps Eko digital stethoscope for heart failure DTx

AI-based heart disease tool wins Future NHS Award

Novartis will appeal Entresto patent setback

FDA points to liver injury with Amgen's Tavneos

Using AI-driven synthetic personas to take your insights fur...

cardiovascular

Editor's Picks